Ultragenyx Pharmaceutical RARE Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's investment proceeds?
- Ultragenyx Pharmaceutical (RARE) reported investment proceeds of $88M in Q1 2026.
- How has Ultragenyx Pharmaceutical's investment proceeds changed year-over-year?
- Ultragenyx Pharmaceutical's investment proceeds decreased by 35.8% year-over-year, from $137M to $88M.
- What is the long-term trend for Ultragenyx Pharmaceutical's investment proceeds?
- Over 3 years (2021 to 2024), Ultragenyx Pharmaceutical's investment proceeds has grown at a -67.6% compound annual growth rate (CAGR), from $92.9M to $3.15M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.